Syndax Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:00 AM Summary

Preliminary Brief of BAC.N presentation 16-May-24 3:00pm GMT

...A. 2024 is set to be a transformational year for Syndax with 2 potential approvals on deck especially for investors who are newer to the story, could you provide a brief description of revumenib and axatilimab? B. I mentioned we have 2 products pending FDA approval in the third quarter of this year. C. We have a PDUFA date first on August 28 for a CSF-1R antibody called axatilimab. D. Secondly, we have Revumenib, our menin inhibitor. E. We would expect a label that covered KMT2AR ALL and AML in both peds and adults. F. They are the leader with Jakafi, which is approved for second-line treatment in chronic graft versus host disease, generally corticosteroids are the first-line treatment. G. We are going to be putting forward 30% of the commercial effort in that 50-50 U.S. commercial partnership. H. So you've guided to an addressable market of around $750 million in the KMT2A rearranged relapsed/refractory setting. I. So the $750 million was for all -- if you treated all patients with KMT2AR....

Brief